Literature DB >> 27911758

Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors.

Bin Ji1,2, Hiroyuki Kaneko1, Takafumi Minamimoto1, Haruhisa Inoue3,2, Hiroki Takeuchi3, Katsushi Kumata4, Ming-Rong Zhang4, Ichio Aoki5, Chie Seki1, Maiko Ono1, Masaki Tokunaga1, Satoshi Tsukamoto6, Koji Tanabe3, Ryong-Moon Shin1, Takeharu Minamihisamatsu1, Seiji Kito6, Barry J Richmond7, Tetsuya Suhara1,2, Makoto Higuchi8,2.   

Abstract

Chemogenetic manipulation of neuronal activities has been enabled by a designer receptor (designer receptor exclusively activated by designer drugs, DREADD) that is activated exclusively by clozapine-N-oxide (CNO). Here, we applied CNO as a functional reporter probe to positron emission tomography (PET) of DREADD in living brains. Mutant human M4 DREADD (hM4Di) expressed in transgenic (Tg) mouse neurons was visualized by PET with microdose [11C]CNO. Deactivation of DREADD-expressing neurons in these mice by nonradioactive CNO at a pharmacological dose could also be captured by arterial spin labeling MRI (ASL-MRI). Neural progenitors derived from hM4Di Tg-induced pluripotent stem cells were then implanted into WT mouse brains and neuronal differentiation of the grafts could be imaged by [11C]CNO-PET. Finally, ASL-MRI captured chemogenetic functional manipulation of the graft neurons. Our data provide the first demonstration of multimodal molecular/functional imaging of cells expressing a functional gene reporter in the brain, which would be translatable to humans for therapeutic gene transfers and cell replacements. SIGNIFICANCE STATEMENT: The present work provides the first successful demonstration of in vivo positron emission tomographic (PET) visualization of a chemogenetic designer receptor (designer receptor exclusively activated by designer drugs, DREADD) expressed in living brains. This technology has been applied to longitudinal PET reporter imaging of neuronal grafts differentiated from induced pluripotent stem cells. Differentiated from currently used reporter genes for neuroimaging, DREADD has also been available for functional manipulation of target cells, which could be visualized by functional magnetic resonance imaging (fMRI) in a real-time manner. Multimodal imaging with PET/fMRI enables the visualization of the differentiation of iPSC-derived neural progenitors into mature neurons and DREADD-mediated functional manipulation along the time course of the graft and is accordingly capable of fortifying the utility of stem cells in cell replacement therapies.
Copyright © 2016 the authors 0270-6474/16/3611545-15$15.00/0.

Entities:  

Keywords:  cell replacement therapy; clozapine-N-oxide (CNO); designer receptor exclusively activated by designer drugs (DREADD); induced pluripotent stem cell (iPSC); positron emission tomography (PET)

Mesh:

Year:  2016        PMID: 27911758      PMCID: PMC6601716          DOI: 10.1523/JNEUROSCI.1279-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  14 in total

1.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Authors:  Juan L Gomez; Jordi Bonaventura; Wojciech Lesniak; William B Mathews; Polina Sysa-Shah; Lionel A Rodriguez; Randall J Ellis; Christopher T Richie; Brandon K Harvey; Robert F Dannals; Martin G Pomper; Antonello Bonci; Michael Michaelides
Journal:  Science       Date:  2017-08-04       Impact factor: 47.728

Review 2.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

Review 3.  The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.

Authors:  Erin J Campbell; Nathan J Marchant
Journal:  Br J Pharmacol       Date:  2018-02-26       Impact factor: 8.739

Review 4.  Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications.

Authors:  Lore M Peeters; Stephan Missault; Aneta J Keliris; Georgios A Keliris
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

5.  Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.

Authors:  Yuji Nagai; Naohisa Miyakawa; Hiroyuki Takuwa; Yukiko Hori; Kei Oyama; Bin Ji; Manami Takahashi; Xi-Ping Huang; Samuel T Slocum; Jeffrey F DiBerto; Yan Xiong; Takuya Urushihata; Toshiyuki Hirabayashi; Atsushi Fujimoto; Koki Mimura; Justin G English; Jing Liu; Ken-Ichi Inoue; Katsushi Kumata; Chie Seki; Maiko Ono; Masafumi Shimojo; Ming-Rong Zhang; Yutaka Tomita; Jin Nakahara; Tetsuya Suhara; Masahiko Takada; Makoto Higuchi; Jian Jin; Bryan L Roth; Takafumi Minamimoto
Journal:  Nat Neurosci       Date:  2020-07-06       Impact factor: 24.884

Review 6.  Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.

Authors:  Jingwei Song; Ruchit V Patel; Massoud Sharif; Anagha Ashokan; Michael Michaelides
Journal:  Mol Ther       Date:  2021-12-01       Impact factor: 11.454

7.  Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders.

Authors:  Patrick H Roseboom; Sascha A L Mueller; Jonathan A Oler; Andrew S Fox; Marissa K Riedel; Victoria R Elam; Miles E Olsen; Juan L Gomez; Matthew A Boehm; Alexandra H DiFilippo; Bradley T Christian; Michael Michaelides; Ned H Kalin
Journal:  Mol Ther       Date:  2021-04-23       Impact factor: 11.454

8.  [11C]deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain.

Authors:  Xuefeng Yan; Sanjay Telu; Rachel M Dick; Jeih-San Liow; Paolo Zanotti-Fregonara; Cheryl L Morse; Lester S Manly; Robert L Gladding; Stal Shrestha; Walter Lerchner; Yuji Nagai; Takafumi Minamimoto; Sami S Zoghbi; Robert B Innis; Victor W Pike; Barry J Richmond; Mark Ag Eldridge
Journal:  J Cereb Blood Flow Metab       Date:  2021-04-14       Impact factor: 6.200

Review 9.  Translational PET applications for brain circuit mapping with transgenic neuromodulation tools.

Authors:  Matthew A Boehm; Jordi Bonaventura; Juan L Gomez; Oscar Solís; Elliot A Stein; Charles W Bradberry; Michael Michaelides
Journal:  Pharmacol Biochem Behav       Date:  2021-02-04       Impact factor: 3.533

10.  18F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography.

Authors:  Feng Hu; Patrick J Morris; Jordi Bonaventura; Hong Fan; William B Mathews; Daniel P Holt; Sherry Lam; Matthew Boehm; Robert F Dannals; Martin G Pomper; Michael Michaelides; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2020-11-25       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.